Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 12/20 | 0.65 |
| ▸ | PDGFRA | P16234 | 11/20 | 0.65 |
| ▸ | BCR | P11274 | 10/20 | 0.65 |
| ▸ | PDGFRB | P09619 | 6/20 | 0.65 |
| ▸ | PRKCA | P17252 | 3/20 | 0.63 |
| ▸ | EGFR | P00533 | 4/20 | 0.63 |
| ▸ | KIT | P10721 | 4/20 | 0.62 |
| ▸ | JAK3 | P52333 | 1/20 | 0.60 |
| ▸ | BTK | Q06187 | 1/20 | 0.60 |
| ▸ | ITK | Q08881 | 1/20 | 0.60 |
| ▸ | SRC | P12931 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23246268 | 0.92 | ABL1 (0.60) | ABL1PDGFRABCRPDGFRBPRKCA | |
| SCHEMBL534524 | 0.91 | ABL1 (0.72) | ABL1PDGFRABCRPDGFRBPRKCA | |
| SCHEMBL17263678 | 0.89 | ABL1 (0.66) | ABL1PDGFRABCRPDGFRBPRKCA | |
| SCHEMBL28891228 | 0.87 | ABL1 (0.64) | ABL1PDGFRABCRPDGFRBPRKCA | |
| SCHEMBL1928420 | 0.87 | PDGFRA (0.61) | ABL1PDGFRABCRPDGFRBPRKCA | |
| SCHEMBL3359726 | 0.87 | ABL1 (0.51) | ABL1PDGFRABCRPDGFRBPRKCA | |
| SCHEMBL29707254 | 0.86 | ABL1 (0.71) | ABL1PDGFRABCRPDGFRBPRKCA | |
| SCHEMBL533540 | 0.86 | ABL1 (0.71) | ABL1PDGFRABCRPDGFRBPRKCA | |
| SCHEMBL12715062 | 0.86 | ABL1 (0.77) | ABL1PDGFRABCRPDGFRBPRKCA | |
| SCHEMBL3947629 | 0.86 | ABL1 (0.62) | ABL1PDGFRABCRPDGFRBPRKCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4045494-B1 | SYNTHESIS OF 6-METHYL-N1-(4-(PYRIDIN-3-YL)PYRIMIDIN-2-YL)BENZENE-1,3-DIAMINE | ESCO ASTER PTE LTD (SG) | 2023-10-11 | — | — | EP | disclosed |
| US-20230065387-A1 | SYNTHESIS OF TYROSINE KINASE INHIBITORS | ESCO ASTER PTE. LTD (SG) | 2023-03-02 | — | — | US | disclosed |
| CN-114585615-A | Synthesis of 6-methyl-N1- (4- (pyridin-3-yl) pyrimidin-2-yl) benzene-1, 3-diamine | 新加坡艺思高艾斯特生物科技有限公司 | 2022-06-03 | — | — | CN | disclosed |
| CN-113968801-A | Nilotinib intermediate and preparation method thereof | 扬子江药业集团南京海陵药业有限公司 | 2022-01-25 | — | — | CN | disclosed |
| US-20210139433-A1 | CRYSTAL FORM OF 3-(4-METHYL-1H-IMIDAZOL-1-YL)-5-TRIFLUOROMETHYLANILINE MONOHYDROCHLORIDE AND USE THEREOF | ARIZEST (SHANGHAI) PHARMATECH CO., LTD. (CN) | 2021-05-13 | — | — | US | disclosed |
| CN-112745300-A | Method for preparing N- (5-carboxyl-2-methylphenyl) -4- (3-pyridine) -2-pyrimidinamine | 杭州浙中医药科技有限公司 | 2021-05-04 | — | — | CN | disclosed |
| WO-2021074138-A1 | SYNTHESIS OF 6-METHYL-N1-(4-(PYRIDIN-3-YL)PYRIMIDIN-2-YL)BENZENE-1,3-DIAMINE | ESCO ASTER PTE. LTD. (SG) | 2021-04-22 | — | — | WO | disclosed |
| CN-110078708-B | Smo/Bcr-Abl dual-targeting inhibitor and synthetic method and application thereof | 东南大学 | 2020-12-11 | — | — | CN | disclosed |
| US-10280153-B2 | Process for the preparation of pure nilotinib and its salt | F.I.S.—Fabbrica Italiana Sintetici S.p.A. (IT) | 2019-05-07 | — | — | US | disclosed |
| US-20180334449-A1 | PROCESS FOR THE PREPARATION OF PURE NILOTINIB AND ITS SALT | F.I.S. - FABBRICA ITALIANA SINTETICI S.P.A. (IT) | 2018-11-22 | — | — | US | disclosed |
| US-7569566-B2 | 4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazol1yl)-3-(trifluoromethyl)phenyl]benzamide or an N-oxide or salts; anticarcinogenic agent (leukaemia) | NOVARTIS AG (CH) | 2009-08-04 | — | — | US | disclosed |
| EP-1532138-B1 | INHIBITORS OF TYROSINE KINASES | NOVARTIS AG (CH) | 2008-11-19 | — | — | EP | disclosed |
| US-20080188656-A1 | Process for the Synthesis of 5- (Methyl-1H-Imidazol-1-Yl) -3- (Trifluoromethyl) -Benzeneamine | NOVARTIS AG (CH) | 2008-08-07 | — | — | US | disclosed |
| US-20080188656-A1 | Process for the Synthesis of 5- (Methyl-1H-Imidazol-1-Yl) -3- (Trifluoromethyl) -Benzeneamine | NOVARTIS AG (CH) | 2008-08-07 | — | — | US | disclosed |
| US-20080188451-A1 | INHIBITORS OF TYROSINE KINASES | BREITENSTEIN WERNER | 2008-08-07 | — | — | US | disclosed |
| US-20070093506-A1 | Inhibitors of tyrosine kinases | BREITENSTEIN WERNER | 2007-04-26 | — | — | US | disclosed |
| US-7169791-B2 | Inhibitors of tyrosine kinases | NOVARTIS AG (CH) | 2007-01-30 | — | — | US | disclosed |
| US-20060167015-A1 | 4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazol1yl)-3-(trifluoromethyl)phenyl]benzamide or an N-oxide or salts; anticarcinogenic agent (leukaemia) | NOVARTIS AG (CH) | 2006-07-27 | — | — | US | disclosed |
| EP-1532138-A1 | INHIBITORS OF TYROSINE KINASES | Novartis AG (CH) | 2005-05-25 | — | — | EP | disclosed |
| WO-2004005281-A1 | INHIBITORS OF TYROSINE KINASES | NOVARTIS AG (CH) | 2004-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093506-A1 | Inhibitors of tyrosine kinases | ABL1, BTK, FLT3 | ABL1 1/4885PDGFRA 382/4885BCR 28/4885 |
| US-20210139433-A1 | CRYSTAL FORM OF 3-(4-METHYL-1H-IMIDAZOL-1-YL)-5-TRIFLUOROMETHYLANILINE MONOHYDROCHLORIDE AND USE THEREOF | ABL1, FYN, FLT3 | ABL1 1/4885PDGFRA 720/4885BCR 147/4885 |
| US-20080188656-A1 | Process for the Synthesis of 5- (Methyl-1H-Imidazol-1-Yl) -3- (Trifluoromethyl) -Benzeneamine | CYP1B1, CYP1A1, PRMT5 | ABL1 10/4885PDGFRA 680/4885BCR 502/4885 |
| US-10280153-B2 | Process for the preparation of pure nilotinib and its salt | ABL1, ABL2, LCK | ABL1 1/4885PDGFRA 398/4885BCR 87/4885 |
| US-20080188451-A1 | INHIBITORS OF TYROSINE KINASES | ABL1, BTK, FLT3 | ABL1 1/4885PDGFRA 382/4885BCR 28/4885 |
| US-20230065387-A1 | SYNTHESIS OF TYROSINE KINASE INHIBITORS | ABL1, ROS1, ABL2 | ABL1 1/4885PDGFRA 211/4885BCR 5/4885 |
| US-20060167015-A1 | 4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazol1yl)-3-(trifluoromethyl)phenyl]benzamide or an N-oxide or salts; anticarcinogenic agent (leukaemia) | ABL1, CDK2, CDKN1A | ABL1 1/4885PDGFRA 440/4885BCR 181/4885 |
| US-20180334449-A1 | PROCESS FOR THE PREPARATION OF PURE NILOTINIB AND ITS SALT | ABL1, ABL2, LCK | ABL1 1/4885PDGFRA 398/4885BCR 87/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.